Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial

[1]  M. McGuckin,et al.  The Bronchiectasis And Low-Dose Erythromycin Study (BLESS) , 2012, ATS 2012.

[2]  S. Holland,et al.  Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. , 2011, Chest.

[3]  H. Imaoka,et al.  Azithromycin and the risk of cardiovascular death. , 2012, The New England journal of medicine.

[4]  W. Boersma,et al.  Long term azithromycin treatment: A randomised placebo-controlled trial in non-CF bronchiectasis; results from the BAT trial , 2011 .

[5]  D. Rubinsztein,et al.  Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. , 2011, The Journal of clinical investigation.

[6]  You-ning Liu,et al.  Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. , 2011, The Journal of antimicrobial chemotherapy.

[7]  J. Maurer.  Trends and Burden of Bronchiectasis-Associated Hospitalizations in the United States, 1993-2006 , 2011 .

[8]  J. DiNicolantonio,et al.  Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[9]  W. Boersma,et al.  Immunomodulatory Effects of Macrolide Antibiotics – Part 2: Advantages and Disadvantages of Long-Term, Low-Dose Macrolide Therapy , 2010, Respiration.

[10]  R. Hubbard,et al.  Trends in bronchiectasis mortality in England and Wales. , 2010, Respiratory medicine.

[11]  B. Rubin,et al.  Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications , 2010, Clinical Microbiology Reviews.

[12]  D Bilton,et al.  British Thoracic Society guideline for non-CF bronchiectasis , 2010, Thorax.

[13]  C. Goss,et al.  Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. , 2010, JAMA.

[14]  D. Hansell,et al.  Mortality in bronchiectasis: a long-term study assessing the factors influencing survival , 2009, European Respiratory Journal.

[15]  E. Chilvers,et al.  Azithromycin therapy for neutrophilic airways disease: myth or magic? , 2009, Thorax.

[16]  A. Chang,et al.  Exacerbations in cystic fibrosis: 4 · Non-cystic fibrosis bronchiectasis , 2008, Thorax.

[17]  T. Ferkol,et al.  Airway inflammation in cystic fibrosis. , 2008, Chest.

[18]  J. Soriano,et al.  Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. , 2007, Chest.

[19]  H. Goossens,et al.  Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study , 2007, The Lancet.

[20]  H. Goossens,et al.  Eff ect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers : a randomised , double-blind , placebo-controlled study , 2007 .

[21]  P. King,et al.  Characterisation of the onset and presenting clinical features of adult bronchiectasis. , 2006, Respiratory medicine.

[22]  J. Jais,et al.  Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial , 2006, Thorax.

[23]  N. Kiper,et al.  Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis 1 , 2006, Journal of clinical pharmacy and therapeutics.

[24]  R. Pauwels,et al.  Relationship between respiratory symptoms and medical treatment in exacerbations of COPD , 2005, European Respiratory Journal.

[25]  M. Martínez-García,et al.  Quality-of-life determinants in patients with clinically stable bronchiectasis. , 2005, Chest.

[26]  M. P. van der Linden,et al.  Antimicrobial Susceptibility of Streptococcus pneumoniae in Eight European Countries from 2001 to 2003 , 2005, Antimicrobial Agents and Chemotherapy.

[27]  L. Saiman,et al.  Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. , 2003, JAMA.

[28]  J. Wedzicha,et al.  COPD exacerbations: definitions and classifications , 2003, European Respiratory Journal.

[29]  M. Rosenthal,et al.  Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial , 2002, The Lancet.

[30]  R. Djukanović,et al.  Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation , 2002, European Respiratory Journal.

[31]  S. Bell,et al.  Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial , 2002, Thorax.

[32]  W. Chaicumpa,et al.  Blinded, placebo-controlled trial of antiparasitic drugs for trichinosis myositis. , 2000, The Journal of infectious diseases.

[33]  Wai Lam,et al.  A pilot study of low-dose erythromycin in bronchiectasis. , 1999, The European respiratory journal.

[34]  A. O'donnell,et al.  Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. , 1998, Chest.

[35]  P. Jones,et al.  Validation of the St. George's Respiratory Questionnaire in bronchiectasis. , 1997, American journal of respiratory and critical care medicine.

[36]  K. Sung,et al.  Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. , 1997, The European respiratory journal.

[37]  D. Naidich,et al.  Bronchiectasis: CT/clinical correlations. , 1995, Seminars in ultrasound, CT, and MR.